Is the use of vitamin K antagonists harmful in patients with CDK?;Anticoagulants de type antivitamines K: Effets délétè res potentiels chez les patients avec une IRC

Revue Medicale Suisse

Volumn 8, Issue 330, 2012, Pages 462-465

  Pham, T T ^a   Saudan, P ^b  

^a SERVICE DE MÉDECINE INTERNE GÉNÉRALE   (Switzerland)

^b Service de Nephrologie   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; 4 HYDROXYCOUMARIN DERIVATIVE; ANTICOAGULANT AGENT; ANTIVITAMINS K; COUMARIN DERIVATIVE; INDENE DERIVATIVE; VITAMIN K GROUP; WARFARIN;

ACUTE KIDNEY FAILURE; ANTICOAGULATION; ATHEROGENESIS; CARBOXYLATION; CHRONIC KIDNEY DISEASE; HEMODIALYSIS; HUMAN; REVIEW; STROKE; VITAMIN K DEFICIENCY; ATHEROSCLEROSIS; BLOOD CLOTTING DISORDER; CEREBROVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; DRUG ANTAGONISM; EVALUATION;

4-HYDROXYCOUMARINS; ACUTE KIDNEY INJURY; ANTICOAGULANTS; ATHEROSCLEROSIS; BLOOD COAGULATION DISORDERS; CEREBROVASCULAR DISORDERS; COUMARINS; HUMANS; INDENES; RENAL INSUFFICIENCY, CHRONIC; VITAMIN K; WARFARIN;

EID: 84860350182     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
2. Turpie AG, Bauer KA, Davidson BL, et al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost 2009;101:68-76.
3. Limdi NA, Beasley TM, Baird MF, et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 2009;20:912-21.
4. Avidor Y, Nadu A, Matzkin H. Clinical significance of gross hematuria and its evaluation in patients receiving anticoagulant and aspirin treatment. Urology 2000;55:22-4.
5. Kapoor KG, Bekaii-Saab T. Warfarin-induced allergic interstitial nephritis and leucocytoclastic vasculitis. Intern Med J 2008;38:281-3.
6. Abt AB, Carroll LE, Mohler JH. Thin basement membrane disease and acute renal failure secondary to gross hematuria and tubular necrosis. Am J Kidney Dis 2000;35:533-6.
7. Kabir A, Nadasdy T, Nadasdy G, Hebert LA. An unusual cause of gross hematuria and transient ARF in an SLE patient with warfarin coagulopathy. Am J Kidney Dis 2004;43:757-60.
8. Brodsky SV, Satoskar A, Chen J, et al. Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts : A report of 9 cases. Am J Kidney Dis 2009;54:1121-6.
9. Brodsky SV, Collins M, Park E, et al. Warfarin therapy that results in an International normalized ratio above the therapeutic range is associated with accelerated progression of chronic kidney disease. Nephron Clin Pract 2010;115:c142-6.
10. ** Brodsky SV, Nadasdy T, Rovin BH, et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int 2011;80:181-9.
11. Drueke TB, Massy ZA. Atherosclerosis in CKD: Dif ferences from the general population. Nat Rev Nephrol 2010;6:723-35.
12. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997;386:78-81.
13. Price PA, Faus SA, Williamson MK. Warfarin cau ses rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998;18:1400-7.
14. Weijs B, Blaauw Y, Rennenberg RJ, et al. Patients using vitamin K antagonists show increased levels of coronary calcification : An observational study in low-risk atrial fibrillation patients. Eur Heart J 2011;32:2555-62.
15. Schlieper G, Westenfeld R, Kruger T, et al. Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J Am Soc Nephrol 2011;22:387-95.
16. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham heart study. JAMA 1994;271:840-4.
17. Stack AG, Bloembergen WE. A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients. Am J Kidney Dis 2001;38:992-1000.
18. Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009;20:705-11.
19. ** Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009;20:2223-33.
20. ** Wizemann V, Tong L, Satayathum S, et al. Atrial fibrillation in hemodialysis patients: Clinical features and associations with anticoagulant therapy. Kidney Int 2010;77:1098-106.